Body Protection Compound-157 10mg — research pentadecapeptide

A 15-amino-acid peptide derived from a protective gastric protein, extensively studied for its role in angiogenesis and in connective and digestive tissue repair models. Stable lyophilized powder. For laboratory research use only.

Research areas

• In vitro angiogenesis
• Tendon / muscle repair models
• Gastrointestinal mucosal integrity (models)

Technical data

What sets BPC-157 apart from other repair peptides

BPC stands for Body Protection Compound. The molecule is a pentadecapeptide — fifteen amino acids — corresponding to a partial fragment of a protein identified in human gastric juice.

What surprises most: its stability. Where most peptides hydrolyse quickly, BPC-157 resists enzymatic degradation relatively well and holds up in the acidic environment of gastric juice, as preclinical pharmacokinetic studies document. That unusual robustness is what made it a privileged object of study for over thirty years.

Mechanism studied

Mechanistic work converges on angiogenesis. A 2020 Scientific Reports study combining ex vivo rat aortic ring assays and in vitro human endothelial cell (HUVEC) work described a precise pathway: BPC-157 induces phosphorylation of the Src kinase, activating caveolin-1, which releases endothelial nitric oxide synthase (eNOS) from its inhibited state — increasing nitric oxide production and endothelium-dependent vasodilation.

Several publications also report overexpression and activation of the VEGFR2 receptor, a key driver of endothelial cell migration, and regulation of FAK-paxillin complexes involved in cell adhesion and migration. These remain working hypotheses, described mostly in cell and animal models.

What the literature shows — and does not

The overwhelming majority of data is preclinical: cell cultures and rodents, mainly rats. Publications report apparent acceleration of repair processes, improved cell survival and migration, and effects on angiogenesis in those models.

A 2025 review in Pharmaceuticals (MDPI) on tendon and muscle tissue concludes that human data remain limited and clinical validation is pending. In short: no large randomised controlled human trial demonstrates efficacy to date. This is precisely why the compound remains a research reagent.

Reconstitution: a worked example

With 2 mL of bacteriostatic water: a 10 mg vial gives 10 ÷ 2 = 5 mg/mL (5,000 mcg/mL), so on a U-100 syringe 10 IU = 0.1 mL = 500 mcg. A 5 mg vial gives 2.5 mg/mL, and the same 10 IU is 250 mcg. Either way, 20 draws of 10 IU per vial.

The most common trap: the volume of water never changes how much peptide is in the vial. Only the volume to draw changes. Our reconstitution calculator computes any other combination live.

Add the solvent slowly down the vial wall, then swirl gently. No vigorous shaking, no vortex — shear denatures peptides.

Storage

Lyophilized powder: -20 °C or below, protected from light and moisture; stable for years when unopened. After reconstitution: 2–8 °C, protected from light, with a reference shelf life of 28 days. For longer storage, frozen aliquots are preferable to repeated freeze-thaw cycles.

Common laboratory mistakes

• Mixing up the two vial sizes when calculating. At equal water volume, a 10 mg vial yields double the concentration of a 5 mg vial.
• Using plain sterile water for a multi-draw vial. Without a preservative, the solution is no longer protected once the stopper has been pierced several times.
• Vortexing the vial. Vigorous agitation denatures peptides, including those reputed to be stable.
• Repeatedly refreezing the reconstituted solution. Each cycle degrades a fraction of the peptide.
• Extrapolating from the literature. The data come from animal models; they do not transfer.